Posted by Michael Wonder on 30 Apr 2021
Cerapedics announces FDA breakthrough device designation granted for P-15L bone graft for the treatment of degenerative disc disease
29 April 2021 - P-15L bone graft is currently being studied in the Company's ASPIRE IDE clinical trial.
Cerapedics today announced that the U.S. FDA has granted breakthrough device designation for its investigational P-15L Bone Graft for the treatment of degenerative disc disease.
